ISSN (O) : 2663 - 046X

A CrossRef Indexed Journal

DOI : 10.34300/26630451

ISSN (P) : 2663 - 0451

IC VALUE : 89.03 (2020)

International Journal of Advanced Medicine (IJAM)
Original Research Paper

Dapagliflozin Efficacy As An Add-on Therapy In Double And Triple-drug Regimens.

Dr. Deepjyoti. Saikia, Dr. Akash. Chathamvelli, Dr. Lizanne Fernandes, Dr. Kadambari. Patil, Dr. Aswathi A

Abstract :

Background: Diabetes is one of the most common diseases compared to others. There are many drugs available in the market to treat diabetes. Still, most of them have adverse drug reactions like hypoglycemia, weight gain, and subtherapeutic drug concentrations. SGLT-2 inhibitors are a new class of drugs used as add-on therapy to treat type-2 Diabetes Mellitus. They act by inhibiting glucose reabsorption and increasing glucose excretion via the kidneys. In an average adult, two kidneys filter about 180g of glucose per day. About 98% of the glucose filtered in the kidneys get reabsorbed in the proximal convoluted tubule back into the bloodstream, which can be inhibited by SGLT-2 inhibitors. Method: A systematic review and meta-analysis were performed on randomized clinical trial data, extracted from PubMed, Cochrane and Embase. All data, including baseline and shift of baseline, standard deviation, and number of participants, were recorded for HbA1c, Fasting blood glucose (FBG), Bodyweight and SBP/DBP.Results: Twelve randomized clinical trials, including 8000 participants, were compared and divided into three groups of drugs: SAXA+DAPA+MET, SAXA+MET and DAPA+MET. The comparison is done for HbA1c (WMD:-6.78; 95% CI:-8.28; P <0.00001) (WMD:-4.88; 95% CI:-6.93; P <0.00001), FBG (SMD: -6.50; 95% CI: -8.55, -4.45; P <0.00001) (SMD: -7.75; 95% CI: -8.84, -6.66; P<0.00005,), body weight (SMD: 0.30; 95% CI: 0.27, 0.33; P =1.00) (SMD: -1.00; 95% CI: -1.90, -0.10; P<0.00001). Conclusion: Dapagliflozin, when given in combination, shows a major improvement in HbA1c and FBG levels and does not affect body weight. It was shown to be more effective when given in triple combination therapy.

Keywords :

Dapagliflozine   meta-analysis   Sexagliptine   Metformin   Type two diabetes mellitus (T2DM)   Sodium-glucose Cotransporter-2 (SGLT2)  

Cite This Article:

DAPAGLIFLOZIN EFFICACY AS AN ADD-ON THERAPY IN DOUBLE AND TRIPLE-DRUG REGIMENS., Dr. Deepjyoti. Saikia, Dr. Akash. Chathamvelli, Dr. Lizanne Fernandes, Dr. Kadambari. Patil, Dr. Aswathi A, INTERNATIONAL JOURNAL OF ADVANCED MEDICINE : Volume-7 | Issue-5 | September-2023

References :

[ Download PDF] [ Number of Downloads : 83 ]

This work is licensed under a Creative Commons Attribution 4.0 International License.
Disclaimer: Articles on International Journal of Advanced Medicine have been previewed and authenticated by the Authors before sending the publication for print.
The Journal, Editor and the editorial board are not entitled or liable to either justify or responsible for inaccurate and misleading data if any.
It is the sole responsibility of the Author concerned. If any queries or infringement occurs

Copyrights ©2023: International Journal of Advanced Medicine (IJAM)